[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$1760b](/topic/$1760b) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Eli Lily beats Q3 earnings raises guidance: EPS: $XXXX vs $XXXX est REV: $17.60B vs $16.02B est Raises FY25 EPS to $23.00-$23.70 vs $XXXXX est $LLY 🟢 +3.4% pre-market" [X Link](https://x.com/TrendSpider/status/1983867820669849976) [@TrendSpider](/creator/x/TrendSpider) 2025-10-30T12:05Z 535.4K followers, 24.3K engagements "$LLY Q3/25 📑 Eli Lilly with a stellar quarter Revenue increased XX% to $17.60B driven by volume growth from Mounjaro and Zepbound 📈 EPS increased by $XXXX to $XXXX on a reported basis and increased by $XXXX to $XXXX on a non-GAAP basis Outlook 2025 FY revenue guidance to be in the range of $63.0B to $63.5B EPS guidance raised to be in the range of $XXXXX to $XXXXX and non-GAAP EPS guidance raised to be in the range of $XXXXX to $XXXXX The Stock is up X% in pre-market" [X Link](https://x.com/RichardWedekin1/status/1983864688107569336) [@RichardWedekin1](/creator/x/RichardWedekin1) 2025-10-30T11:52Z 4105 followers, XXX engagements "$NVO busy spending money on acquisitions. Value = unclear. Meanwhile $LLY with another great quarter. Maybe I should be investing in $LLY instead of $NVO Eli Lilly's Q3 numbers: - Revenue: $17.60B (Est. $16.07B) 🟢+54% YoY - EPS (Non-GAAP): $XXXX (Est. $5.89) 🟢 - Gross Margin: 82.9%🟢 FY25 Guidance raised -- - Revenue: $63.0B$63.5B (Est. $61.63B) 🟢 - EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) 🟢 $LLY CEO David Ricks: Lilly delivered another strong quarter with XX% revenue growth year-over-year driven by continued demand for our incretin portfolio". " We advanced Orforglipron through four" [X Link](https://x.com/TacticzH/status/1983854319381201002) [@TacticzH](/creator/x/TacticzH) 2025-10-30T11:11Z 29.5K followers, 28.8K engagements "Eli Lilly $LLY Q3-25. Results: 📊 Adj. EPS: $XXXX 🟢 💰 Revenue: $17.60B 🟢 📈 Net Income: $5.58B 🔎 Mounjaro and Zepbound drove massive volume growth; orforglipron progressed through four Phase X trials with obesity submissions planned by year-end" [X Link](https://x.com/Earnings_Time/status/1983849042271728007) [@Earnings_Time](/creator/x/Earnings_Time) 2025-10-30T10:50Z 13.3K followers, 17.2K engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Eli Lily beats Q3 earnings raises guidance: EPS: $XXXX vs $XXXX est REV: $17.60B vs $16.02B est Raises FY25 EPS to $23.00-$23.70 vs $XXXXX est $LLY 🟢 +3.4% pre-market"
X Link @TrendSpider 2025-10-30T12:05Z 535.4K followers, 24.3K engagements
"$LLY Q3/25 📑 Eli Lilly with a stellar quarter Revenue increased XX% to $17.60B driven by volume growth from Mounjaro and Zepbound 📈 EPS increased by $XXXX to $XXXX on a reported basis and increased by $XXXX to $XXXX on a non-GAAP basis Outlook 2025 FY revenue guidance to be in the range of $63.0B to $63.5B EPS guidance raised to be in the range of $XXXXX to $XXXXX and non-GAAP EPS guidance raised to be in the range of $XXXXX to $XXXXX The Stock is up X% in pre-market"
X Link @RichardWedekin1 2025-10-30T11:52Z 4105 followers, XXX engagements
"$NVO busy spending money on acquisitions. Value = unclear. Meanwhile $LLY with another great quarter. Maybe I should be investing in $LLY instead of $NVO Eli Lilly's Q3 numbers: - Revenue: $17.60B (Est. $16.07B) 🟢+54% YoY - EPS (Non-GAAP): $XXXX (Est. $5.89) 🟢 - Gross Margin: 82.9%🟢 FY25 Guidance raised -- - Revenue: $63.0B$63.5B (Est. $61.63B) 🟢 - EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) 🟢 $LLY CEO David Ricks: Lilly delivered another strong quarter with XX% revenue growth year-over-year driven by continued demand for our incretin portfolio". " We advanced Orforglipron through four"
X Link @TacticzH 2025-10-30T11:11Z 29.5K followers, 28.8K engagements
"Eli Lilly $LLY Q3-25. Results: 📊 Adj. EPS: $XXXX 🟢 💰 Revenue: $17.60B 🟢 📈 Net Income: $5.58B 🔎 Mounjaro and Zepbound drove massive volume growth; orforglipron progressed through four Phase X trials with obesity submissions planned by year-end"
X Link @Earnings_Time 2025-10-30T10:50Z 13.3K followers, 17.2K engagements
/topic/$1760b/posts